Share on StockTwits

Thoratec (NASDAQ: THOR) was the recipient of a ratings changes during the seven days:

  • Thoratec was downgraded by analysts at Goldman Sachs from a “buy” rating to a “neutral” rating. They now have a $28.00 price target on the stock, down previously from $38.00.
  • Thoratec had its price target lowered by analysts at Oppenheimer from $41.00 to $35.00. They now have an “outperform” rating on the stock.
  • Thoratec was downgraded by analysts at Credit Suisse from an “outperform” rating to a “neutral” rating. They now have a $27.00 price target on the stock, down previously from $40.00.
  • Thoratec had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $30.00 price target on the stock, down previously from $41.00.
  • Thoratec was downgraded by analysts at Bank of America to a “neutral” rating.
  • Thoratec had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $35.00 price target on the stock, down previously from $40.00.
  • Thoratec was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.
  • Thoratec had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $28.00 price target on the stock, down previously from $39.00.
  • Thoratec had its “neutral” rating reaffirmed by analysts at Zacks. They now have a $24.00 price target on the stock. Zacks‘ analyst wrote, “Thoratec Corp.’s 2014-second quarter earnings dropped 34.1% year over year to $0.29 and lagged the Zacks Consensus Estimate by $0.02. Revenues also fell 9.5% to $118.1 million in the quarter and missed the mark. The company faced difficult quarterly comparisons in the businesses across Europe and Japan and a decline in HeartMate II sales. For fiscal 2014, the company lowered its adjusted earnings per share guidance to $1.25-$1.35 and revenue guidance to a range of $455 to $470 million. We maintain our Neutral recommendation on Thoratec and set a target price of $24.00.”
  • Thoratec was downgraded by analysts at Northland Securities from an “outperform” rating to a “market perform” rating. They now have a $26.00 price target on the stock, down previously from $46.00.

Shares of Thoratec Co. (NASDAQ:THOR) traded up 0.25% during mid-day trading on Wednesday, hitting $23.259. The stock had a trading volume of 794,920 shares. Thoratec Co. has a 1-year low of $22.50 and a 1-year high of $43.58. The stock’s 50-day moving average is $32.1 and its 200-day moving average is $33.71. The company has a market cap of $1.309 billion and a P/E ratio of 19.85.

Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.